WEBULL

Will a Veteran CFO Reshape Alkermes' (ALKS) Financial Strategy Amid Pipeline Challenges?

Simply Wall St · 09/17/2025 20:22
  • Alkermes has appointed Joshua Reed as Chief Financial Officer, effective September 15, 2025, adding an executive with over 30 years of financial leadership in the biopharmaceutical sector to its management team.
  • Reed's background, spanning positions at Omega Therapeutics, Aldeyra Therapeutics, and Bristol-Myers Squibb, signals an emphasis on experienced financial stewardship as Alkermes looks to address its pipeline and revenue challenges.
  • We will explore how Reed’s appointment as CFO may influence Alkermes’ investment narrative, especially regarding its financial strategy and pipeline management.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Alkermes Investment Narrative Recap

Shareholders in Alkermes need confidence in the company’s ability to transition from recent one-time revenue benefits to more sustainable growth through its neuroscience pipeline and product portfolio. The appointment of Joshua Reed as CFO introduces experienced financial leadership, but does not materially change the immediate importance of clinical progress in the orexin agonist programs or address the near-term risk of normalizing gross-to-net revenue adjustments, which could dampen growth as these tailwinds recede.

One of the most relevant recent announcements is Alkermes’ update on ALKS 2680 for narcolepsy, highlighted by new research presented at SLEEP 2025. This development remains closely tied to the company’s future catalysts, as successful expansion of the orexin agonist pipeline could help offset risks associated with its concentrated portfolio and provide new, multi-indication revenue streams.

On the other hand, investors should be attentive to the possibility that revenue normalization after recent one-time adjustments ...

Read the full narrative on Alkermes (it's free!)

Alkermes' outlook points to $1.4 billion in revenue and $169.0 million in earnings by 2028. This reflects a 1.3% annual revenue decline and a decrease of $179.1 million in earnings from the current $348.1 million.

Uncover how Alkermes' forecasts yield a $41.59 fair value, a 52% upside to its current price.

Exploring Other Perspectives

ALKS Community Fair Values as at Sep 2025
ALKS Community Fair Values as at Sep 2025

Three individual estimates from the Simply Wall St Community place Alkermes’ fair value between US$41.59 and US$54.70 per share. Against this range of viewpoints, the risk of weaker revenue as one-time benefits fade highlights why you may want to compare community forecasts and professional consensus.

Explore 3 other fair value estimates on Alkermes - why the stock might be worth just $41.59!

Build Your Own Alkermes Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.